Skip to main content
NewslettersWatchlist

Aptose Biosciences Inc(APS-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.3350
Day High0.4000
Open:0.3900
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
GlobeNewswire
Aptose Reports Results for the Third Quarter 2024
GlobeNewswire
Aptose Announces Results from Special Meeting of Shareholders
AI-generated - The Globe and Mail
Aptose Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (APS)
GlobeNewswire
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Stock Target Advisor
Aptose Biosciences Inc: Analyst Forecasts and Stock Analysis
AI-generated - The Globe and Mail
Aptose Biosciences: Top 10 Undervalued Growth Stocks on TSX (APS)
AI-generated - The Globe and Mail
Aptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)
GlobeNewswire
Aptose Announces Adjournment of its Special Meeting of Shareholders
GlobeNewswire
Aptose Reports Results for the Second Quarter 2024
AI-generated - The Globe and Mail
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (APS)
GlobeNewswire
Aptose Announces Receipt of Deficiency Notice from Nasdaq
AI-generated - The Globe and Mail
Aptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)
AI-generated - The Globe and Mail
Aptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)
GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
GlobeNewswire
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AI-generated - The Globe and Mail
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (APS)
GlobeNewswire
Aptose Reports Results for the First Quarter 2024

Profile

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.